Precision BioSciences (DTIL) announced that the FDA has granted Rare Pediatric Disease Designation for PBGENE-DMD for the treatment of Duchenne muscular dystrophy.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DTIL:
- Precision BioSciences: Promising Gene Editing Platform Targets Chronic HBV and DMD with Strategic Focus
- Precision BioSciences Holds Annual Stockholder Meeting
- Buy Rating for Precision BioSciences: Promising ARCUS-Based Programs and Strong Gene Editing Prospects
- Precision BioSciences: Strategic Focus on ARCUS Platform and Promising DMD Treatment Drives Buy Rating
- Precision BioSciences Reports Q1 2025 Financial Results